Page 221 - Remedial Andrology

1044. Ziegelmann, M.J., et al. Restoration of Penile Function and Patient Satisfaction with Intralesional
Collagenase Clostridium Histolyticum Injection for Peyronie’s Disease. J Urol, 2016. 195: 1051.
https://pubmed.ncbi.nlm.nih.gov/26476353
1045. Yang, K.K., et al. Peyronie’s Disease and Injectable Collagenase Clostridium histolyticum: Safety,
Efficacy, and Improvements in Subjective Symptoms. Urology, 2016. 94: 143.
https://pubmed.ncbi.nlm.nih.gov/27211926
1046. Anaissie, J., et al. Impact of Number of Cycles of Collagenase Clostridium Histolyticum on
Outcomes in Patients With Peyronie’s Disease. Urology, 2017. 100: 125.
https://pubmed.ncbi.nlm.nih.gov/27816605
1047. Abdel Raheem, A., et al. Safety and effectiveness of collagenase clostridium histolyticum in the
treatment of Peyronie’s disease using a new modified shortened protocol. BJU Int, 2017. 120: 717.
https://pubmed.ncbi.nlm.nih.gov/28612401
1048. Capece, M., et al. Collagenase clostridium histolyticum for the treatment of Peyronie’s disease: a
prospective Italian multicentric study. Andrology, 2018. 6: 564.
https://pubmed.ncbi.nlm.nih.gov/29733116
1049. Cocci, A., et al. Predictors of treatment success after collagenase Clostridium histolyticum injection
for Peyronie’s disease: development of a nomogram from a multicentre single-arm, non-placebo
controlled clinical study. BJU Int, 2018. 122: 680.
https://pubmed.ncbi.nlm.nih.gov/29791971
1050. Carson, C.C., 3rd, et al. Analysis of the clinical safety of intralesional injection of collagenase
Clostridium histolyticum (CCH) for adults with Peyronie’s disease (PD). BJU Int, 2015. 116: 815.
https://pubmed.ncbi.nlm.nih.gov/25818264
1051. El-Khatib, F.M., et al. Management of Peyronie’s disease with collagenase Clostridium histolyticum
in the acute phase. World J Urol, 2020. 38: 299.
https://pubmed.ncbi.nlm.nih.gov/31093703
1052. Cocci, A., et al. Efficacy of Collagenase Clostridium histolyticum (Xiapex(®)) in Patients with the
Acute Phase of Peyronie’s Disease. Clin Drug Investig, 2020. 40: 583.
https://pubmed.ncbi.nlm.nih.gov/32342279
1053. Nguyen, H.M.T., et al. Safety and Efficacy of Collagenase Clostridium histolyticum in the Treatment
of Acute Phase Peyronie’s Disease: A Multi-institutional Analysis. Urology, 2020. 145: 147.
https://pubmed.ncbi.nlm.nih.gov/32777367
1054. Duncan, M.R., et al. Regulation of the proliferation and biosynthetic activities of cultured human
Peyronie’s disease fibroblasts by interferons-alpha, -beta and -gamma. Scand J Urol Nephrol, 1991.
25: 89.
https://pubmed.ncbi.nlm.nih.gov/1651559
1055. Hellstrom, W.J., et al. Single-blind, multicenter, placebo controlled, parallel study to assess the
safety and efficacy of intralesional interferon alpha-2B for minimally invasive treatment for Peyronie’s
disease. J Urol, 2006. 176: 394.
https://pubmed.ncbi.nlm.nih.gov/16753449
1056. Kendirci, M., et al. The impact of intralesional interferon alpha-2b injection therapy on penile
hemodynamics in men with Peyronie’s disease. J Sex Med, 2005. 2: 709.
https://pubmed.ncbi.nlm.nih.gov/16422829
1057. Stewart, C.A., et al. Intralesional Injection of Interferon-alpha2b Improves Penile Curvature in Men
with Peyronie’s Disease Independent of Plaque Location. J Urol, 2015. 194: 1704.
https://pubmed.ncbi.nlm.nih.gov/26144333
1058. Cipollone, G., et al. [Betamethasone versus placebo in Peyronie’s disease]. Arch Ital Urol Androl,
1998. 70: 165.
https://pubmed.ncbi.nlm.nih.gov/9823662
1059. Desanctis, P.N., et al. Steroid injection therapy for Peyronie’s disease: a 10-year summary and
review of 38 cases. J Urol, 1967. 97: 114.
https://pubmed.ncbi.nlm.nih.gov/6016195
1060. Gennaro, R., et al. Intralesional hyaluronic acid: an innovative treatment for Peyronie’s disease. Int
Urol Nephrol, 2015. 47: 1595.
https://pubmed.ncbi.nlm.nih.gov/26257044
1061. Zucchi, A., et al. Intralesional Injection of Hyaluronic Acid in Patients Affected With Peyronie’s
Disease: Preliminary Results From a Prospective, Multicenter, Pilot Study. Sex Med, 2016. 4: e83.
https://pubmed.ncbi.nlm.nih.gov/26984291
1062. Munoz-Rangel, C.A., et al. Minimally Invasive Therapy Using Intralesional OnabotulinumtoxinA in
Peyronie’s Disease. Urol J, 2015. 12: 2105.
https://pubmed.ncbi.nlm.nih.gov/25923158

220 SEXUAL AND REPRODUCTIVE HEALTH - MARCH 2021